A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Low-Blast Acute Myelogenous Leukemia
A study for patients with MDS, Chronic Myelomonocytic Leukemia (CMML) or Acute Myelogenous Leukemia (MDS) using study drug pevonedistat
Sponsor: Millennium Pharmaceuticals, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAQ7445
U.S. Govt. ID: NCT02610777
Contact: Mark Frattini: 212-851-4872 / mgf2122@cumc.columbia.edu
Additional Study Information: Pevonedistat is currently being studied in humans with advanced solid tumors and acute myelogenous leukemia (AML). The current study is designed to evaluate pevonedistat in combination with azacitidine in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and low-blast AML. This study will assess whether taking pevonedistat in combination with azacitidine increases the amount of time you live without any worsening of your disease when compared to azacitidinealone.
This study is closed
Investigator
Mark Frattini, MD, PhD
Do You Qualify?
Do you have a confirmed diagnosis of MDS, nonproliferative CMML, or low-blast AML? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Mark Frattini
mgf2122@cumc.columbia.edu
212-851-4872
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE